GlassScriptPhysician profile
Geoffrey Shouse
NPI 1568721116
$143,180.40
in general payments reported to CMS, 2019-2025
21 companies · $37K in 2025
The $37K reported for 2025 was more than what 91% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,114 · 2020: $8,770 · 2021: $8,124 · 2022: $9,522 · 2023: $43K · 2024: $36K · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $69K · Consulting Fee: $27K · Honoraria: $10K · Travel and Lodging: $6,550 · Food and Beverage: $2,782 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $68,985.00 |
| Consulting Fee | $27,105.00 |
| Honoraria | $10,220.00 |
| Travel and Lodging | $6,549.87 |
| Food and Beverage | $2,781.64 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $74,397.18 | 2020-2025 | Yescarta |
| Beigene USA, INC. | $42,566.26 | 2020-2024 | Brukinsa |
| Adc Therapeutics America, INC. | $11,840.24 | 2025 | |
| Abbvie INC. | $4,318.25 | 2022-2025 | |
| Beone Medicines USA, INC. | $4,047.71 | 2025 | Brukinsa |
| Ipsen Biopharmaceuticals, INC | $2,220.00 | 2024 | Tazverik |
| Astrazeneca Pharmaceuticals LP | $2,220.00 | 2023 | Calquence |
| Genentech, INC. | $795.49 | 2019 | |
| Celgene Corporation | $164.00 | 2019-2025 | |
| Seagen INC. | $154.16 | 2022 | |
| Amgen INC. | $125.00 | 2019 | |
| Incyte Corporation | $104.96 | 2019 | |
| Pfizer INC. | $92.48 | 2024 | |
| Astrazeneca Uk Limited | $55.00 | 2022 | |
| Genmab U.S., INC. | $34.42 | 2024 | Epkinly |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $25.91 | 2024 | Vanflyta |
| Rigel Pharmaceuticals, INC. | $19.34 | 2025 | Gavreto, Rezlidhia, Tavalisse |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geoffrey Shouse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.